Hueser, C., Dieterich, P., Singh, J., Shah-Hosseini, K., Allekotte, S., Lehmacher, W., Compalati, E. and Moesges, R. (2017). A 12-week DBPC dose-finding study with sublingual monomeric allergoid tablets in house dust mite-allergic patients. Allergy, 72 (1). S. 77 - 85. HOBOKEN: WILEY. ISSN 1398-9995

Full text not available from this repository.

Abstract

BackgroundIn sublingual immunotherapy, optimal doses are a key factor for therapeutic outcomes. The aim of this study with tablets containing carbamylated monomeric house dust mite allergoids was to determine the most effective and safe dose. MethodsIn this double-blind, placebo-controlled dose-finding study, 131 patients with house dust mite-induced allergic rhinoconjunctivitis were randomized to 12-week treatments with 300 UA/day, 1000 UA/day, 2000 UA/day, 3000 UA/day or placebo. Conjunctival provocation tests (CPT) were performed before, during and after treatment. The change in mean allergic severity (primary endpoint), calculated from the severity of the CPT reaction, and the proportion of patients with an improved CPT threshold (secondary endpoint) determined the treatment effect. ResultsThe mean allergic severity decreased in all groups, including the placebo group. It was lower in all active treatment groups (300 UA/day: 0.14, 1000 UA/day: 0.15, 2000 UA/day: 0.10, 3000 UA/day: 0.15) than in the placebo group (0.30). However, this difference was not statistically significant (P < 0.1). The percentage of patients with an improved CPT threshold was higher in the active treatment groups (300 UA/day: 73.9%; 1000 UA/day: 76.0%; 2000 UA/day: 88.5%; 3000 UA/day: 76.0%) than in the placebo group (64.3%). The difference between placebo and 2000 UA/day was statistically significant (P = 0.04). In 13 (10%) exposed patients, a total of 20 treatment-related adverse events of mild severity were observed. ConclusionsThe 12-week daily treatment using 2000 UA/day monomeric allergoid sublingual tablets is well tolerated and reduces the CPT reaction in house dust mite-allergic patients.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Hueser, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dieterich, P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Singh, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Shah-Hosseini, K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Allekotte, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lehmacher, W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Compalati, E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Moesges, R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-248110
DOI: 10.1111/all.12913
Journal or Publication Title: Allergy
Volume: 72
Number: 1
Page Range: S. 77 - 85
Date: 2017
Publisher: WILEY
Place of Publication: HOBOKEN
ISSN: 1398-9995
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
CLINICAL-EFFICACY; RESPIRATORY ALLERGY; PROVOCATION TEST; IMMUNOTHERAPY; RHINITIS; CONJUNCTIVAL; RHINOCONJUNCTIVITIS; EXTRACT; TRIALS; SAFETYMultiple languages
Allergy; ImmunologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/24811

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item